US Patent 10,933,061: Critical claim-level review and US patent landscape for downstream freedom-to-operate
What are the independent claims in US Patent 10,933,061 and what do they cover?
No content of “The claims are:” was provided, and the claim set is required to perform a claim-by-claim infringement, scope, and design-around analysis. Without the text of the claims (including claim numbering and any claim dependencies), a complete and accurate landscape tying claim scope to potential earlier art, common infringement theories, and design-around routes cannot be produced.
Which US patents are most relevant to US 10,933,061 (same assignee, same technology family, same priority)?
No patent-family identifiers (assignee, application/priority numbers, publication numbers) were provided for US 10,933,061, and the patent document itself was not supplied. Without the bibliographic data and the claim text, it is not possible to map the family members, related continuations/divisionals, or cite the most relevant earlier or neighboring US patents with defensible accuracy.
What earlier patents and prior art most likely anticipate or render obvious the claim scope?
A prior-art analysis requires at minimum: (1) the full claim text and dependent claim limitations; (2) the active ingredient/drug product context (if any); (3) the technology class (small molecule, biologic, formulation, device, method of treatment); and (4) the earliest priority date of US 10,933,061 to anchor novelty and obviousness. None of these inputs were provided, and the claim text is missing.
How strong is the patent estate for US 10,933,061 in enforcement terms?
Strength depends on claim construction indicators (indefiniteness risk, functional claiming, breadth of ranges), prosecution history (amendments, narrowing, disclaimers), and whether there are overlapping claims across continuations. None of this is available because US 10,933,061 claim text and prosecution context were not provided.
What formulation or method-of-use claims would block generic or biosimilar alternatives?
This depends entirely on whether the patent claims cover: composition (active ingredient + excipients, polymorph/crystal form, particle size, salt, co-crystal), dosage form (film coating, ophthalmic formulation, sustained release), or methods of treatment (patient selection, dosing regimen, endpoints). Claim text is required to categorize and then identify likely non-infringing alternatives.
When does US 10,933,061 lose exclusivity (expiration, term adjustments, terminal disclaimers)?
Expiration and exclusivity timelines require the patent’s filing date, any granted patent term adjustment (PTA), any terminal disclaimer, and the presence of regulatory exclusivities (Hatch-Waxman) or pediatric extensions. None of that information was supplied.
What Orange Book status affects enforcement for US 10,933,061?
Orange Book status requires knowing the FDA application(s) and the listed patents for the relevant drug product. Without the drug product name and without the patent’s Orange Book listing linkage, an Orange Book status analysis cannot be completed accurately.
Is US 10,933,061 being challenged through Paragraph IV certifications?
Paragraph IV requires knowledge of the listed drug, FDA application numbers, and the patent being asserted in any litigation. No FDA listing or litigation docket information was provided.
What patent litigation and settlement agreements involve US 10,933,061?
Litigation analysis requires docket numbers, parties, asserted claims, and settlement terms. None of these were provided, and there is no claim text to map “asserted claim scope” to likely validity/infringement positions.
How does US 10,933,061 compare with competing patents by claim breadth and remaining runway?
Comparison requires: a defined competitor set (specific patent publications/patents), claim charts or at least independent claim scope summaries, and remaining life. Without the claim text and family identifiers, no defensible comparison is possible.
Key Takeaways
- US Patent 10,933,061 claim-level analysis and a comprehensive patent landscape cannot be completed because the claim set text was not provided and bibliographic identifiers needed for family mapping were not supplied.
FAQs
- What independent claim types (composition vs method-of-use vs process) drive the infringement risk for US 10,933,061?
- How do dependent claim limitations in US 10,933,061 narrow or broaden the effective protection?
- How is US 10,933,061 likely construed for claim scope under US courts’ claim construction standards?
- What is the typical design-around pathway when a patent’s novelty hinges on a specific range or parameter?
- How does Orange Book listing status change the enforcement leverage for a US patent like 10,933,061?
References
-
